Death during Dental Anaesthesia SIR,-With reference to your medicolegal report (2 February, p. 207) entitled "Death during Dental Anaesthesia" I wish to make the following comments.
In evidence Mr Regarding Mr. Williams's "six breaths of nitrous oxide"; during the course, in lectures and demonstrations, he was repeatedly warned of the dangers of anoxia. This point receives frequent mention in the S.A.A.D. Manual, 3rd edition, which he was advised to study. The following extracts are appropriate to the case. P. 2, para. 1.-"The rules of safety are clearly defined. Until they can be adhered to, the method must not be attempted." P. 9, Recommendations, no. 2-"Oxygen restriction below 20% is never needed and should never be tolerated. Any technique . . . in which there may be a temptation to restrict oxygen . . . should be carefully avoided." P. 16, Criteria, para. 2 "Oxygen restriction neither follows the administration of methohexitone nor is it necessary in any of the techniques employing it." P. 31, para. 3-"Many complications can occur from abuse of the method. At all times the fundamental principles of safety must be strictly followed." P. 38, Care and Control, para. 4.-"The dangers of anoxia must be avoided by never British Academy of Psychopharmacology SIR,-For many years the United Kingdom has lagged behind other countries in having no specific organization dedicated to psychopharmacology. Thus a number of other countries have established their own national organizations that are affiliated to the Collegitun Internationale NeuroPsychopharmacologicum (C.I.N.P.), one of the best known of these being the American College of Neuro-Psychopharmacology.
In view of the considerable contributions made by our country to psychopharmacology it appears to us that the present situation is anomalous and that the time has come to establish a national organization in Britain. To avoid confusion with the royal colleges we propose that this organization be called "The British Academy of Psychopharmacology."
We believe that there is a particular need to focus attention on the importance of dru treatment in psychiatry in the eyes of both the young clinician and the research scientist. Therefore -the objects of the academy will be to further research in psychopharnacology, both clinical and experimental, and to improve the qual,ity and standards of psychotropic drug evaluation. This can be accomplished by means of the spoken and written word through the media of meetings, study groups, and publications.
We propose to call a meeting in the near future of all those memnbers of the profession who may have an active interest in psychopharmacology for the purpose of determining the constitution of the academy, to elect officers, and to consider the academy's policy, particularly in relation to the pharmaceutical industry. To this end we have drafted some suggestions and would be pleased to forward these to any interested member of the profession. We would also like to receive suggestions and comments concerning the establishment of the academy, and invite those interested to communicate with any one of the undersigned. - 5II-Fibrnogen and Blocking of the Thyroid Gland SmI,-In almost all papers concerning the diagnosis of venous thrombosis with 251-fibrinogen the blocking of the thyroid gland by 100 mg of sodium iodide or 150 mg of potassium iodide is described. The iodide is given orally 24 hours before injection of '25I-fibrinogen and the dose repeated daily for three weeks.
Radioiodine studies of thyroid blocking and recovery' have shown that the time taken to achieve the blocked state would appear to be about half an hour after giving 100 mg of iodine orally. At that dose the recovery from the blocked state to 1 % of normal uptake is 24 hours and to 100%°of normal uptake eight days. The 24-hour blocking time is a disadvantage in the '25I-fibrinogen method. With no blocking time the investigation can start immediately.
Because of the relatively low fraction of free iodine in the labelled fibrinogen the amount of radioiodine taken up in the thyroid during the first two hours can be neglected. Thus if iodide is given orally together with the 125I-fibrinogen, in practice the thyroid will be blocked as effectively as if iodide were given before injection of the 125I-fibrinogen. As a suitable blocking dose I initially give 400 mg of potassium iodide orally and follow it with 200 mg daily for the next three weeks. Anticonvulsant Osteomalacia and Vitamin D Sm,-Dr. Claus Christiansen and his colleagues (22 December, p. 695), using photon absorptiometry, have demonstrated in their careful paper a decreased bone mineral content (B.M.C.) in the forearm bones of epileptic subjects compared with a normal control population. B.M.C. was lowest in those epileptics with hypocalcaemia and/or increased plasma alkaline phosphatase. The authors also demonstrated a significant increase in B.M.C. in epileptics when they were treated with 2,000 IU of vitamin D3 daily. While we accept that photon absorptiometry may offer a new and sensitive method for studying abnormalities of bone mineralization, we feel we should attempt to qualify the enthusiasm with which the authors diagnose the presence of "anticonvulsant osteomalacia." They consider that the presence of any of the followingincreased serum alkaline phosphatase, decreased serum calcium, and decreased B.M.C.-indicates the presence of "anticonvulsant osteomalacia." One of us has previously demonstrated, using polyacrylamide gel electrophoresis, that the significant increase in plasma total alkaline phosphatase levels in adult epileptics is due to an increase in the hepatic isoenzyme.1 2 Mean levels of alkaline phosphatase of bone origin were no higher in adult epileptics than -in normal adults. Also mean urnary levels of total hydroxyproline were no longer higher in adult epileptics than in normal adults (33-1 and 35-8 mg per 24 hours respectively). In this situation determination of plasma total alkaline phosphatase is of limited value in the diagnosis of osteomalacia.
Hypocalcaemia is common in epileptic subjects without other biochemical indications of osteomalacia and has been found in the absence of histological abnormalities in bone. 3 The lack of increase in serum calcium levels in epilep:.ic subjects which these authors found after treatment with 2,000 IU of vitamin D3 daily is in agreement with other studies; epileptic subjects with marginal hypocalcaemia were treated with even larger doses, either 10,000 or 50,000 IU vitamin D daily for seven months without effect upon plasma calcium levels. 4 The presence of hypocalcaemia without other biochemical abnormality in epileptic subjects may therefore not always indicate osteomalacia but may instead reflect a second anticonvulsant effect upon calcium metabolism, as has been suggested by others. 5 An association between epilepsy and osteoporosis has been recognized for some time6 and in our experience is appreciably more common than a finding of osteomalacia. A lowered B.M.C. has not been reported to distinguish between these forms of skeletal rarefaction.
Whatever the reason for diminished B.M.C. the effects of treatment with small doses of vitamin D on B.M.C. are at variance with the results of calcium balance studies, and better understanding of the relation between these measurements is clearly necessary. From their data the authors calculate that the change in B.M.C. is equivalent to a positive calcium balance of 300 mg daily. Such changes do not occur during the treatment of osteoporosis of any origin since the disease does not satisfactorily respond to treatment.6 While large positive balances certainly result from the treatment of osteomalacia with adequate vitamin D, "anticonvulsant osteomalacia" typically shows great resistance to the low doses (2,000 IU daily) which were used by these authors. 7 We should therefore like to emphasize that the question of prophylactic vitamin D in the region of 2,000 IU daily merely a cost-benefit exercise, since doses of vitamin D in the region of 2,000 IU daily may prove insufficient either to heal anticonvulsant rickets or even to prevent its occurrence. 9 We support the final conclusion of these authors concerning the necessity for close clinical supervision of all epileptic
